Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Endocrine Disorders
Published in: BMC Endocrine Disorders 1/2019

Open Access 01-12-2019 | Insulins | Research article

Association between plasma adipsin level and mild cognitive impairment in Chinese patients with type 2 diabetes: a cross-sectional study

Authors: Dan Guo, Yang Yuan, Rong Huang, Sai Tian, Jiaqi Wang, Hongyan Lin, Ke An, Jin Han, Shaohua Wang

Published in: BMC Endocrine Disorders | Issue 1/2019

Login to get access

Abstract

Background

The adipokine adipsin contributes to insulin resistance (IR), inflammation, and obesity, which are all regarded as high-risk factors for mild cognitive impairment (MCI) in patients with type 2 diabetes mellitus. This research aimed to uncover the role of adipsin in Chinese type 2 diabetes mellitus (T2DM) population with early cognitive dysfunction and determine whether adipsin contributes to diabetic MCI caused by IR.

Methods

In our study, 126 patients with T2DM were enrolled. The Montreal Cognitive Assessment (MoCA) was used to assess cognitive impairment. Demographic data and neuropsychological test results were evaluated. Plasma adipsin level was measured by enzyme-linked immunosorbent assay.

Results

The MCI group (n = 57) presented higher plasma adipsin levels compared with the healthy controls (p = 0.018). After adjustment for educational attainment, and age, begative correlations were found between plasma adipsin levels and MoCA, Mini Mental State Exam, and Verbal Fluency Test scores(r = − 0.640, p < 0.001; r = − 0.612, p < 0.001; r = − 0.288, p = 0.035; respectively). Correlation analysis demonstrated that adipsin levels were significantly positively correlated with fasting C-peptide; homeostasis model of assessment for insulin resistance (HOMA-IR) (r = 0.368, p < 0.001; r = 0.494, p < 0.001; respectively). Multivariable regression analysis further indicated that high plasma adipsin level was a significant independent determinant of MCI in the Chinese population withT2DM (p = 0.017).

Conclusions

Elevated plasma adipsin level was associated with MCI in Chinese T2DM patients. Further large-scale studies should be designed to determine whether adipsin is linked to IR-associated susceptibility to early cognitive decline in T2DM patients.
Literature
1.
Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–21.PubMedCrossRef
2.
van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ. Brain imaging in patients with diabetes: a systematic review. Diabetes Care. 2006;29(11):2539–48.PubMedCrossRef
3.
Mariani E, Monastero R, Mecocci P. Mild cognitive impairment: a systematic review. J Alzheimers Dis. 2007;12(1):23–35.PubMedCrossRef
4.
Li W, Huang E. An update on type 2 diabetes mellitus as a risk factor for dementia. J Alzheimers Dis. 2016;53(2):393–402.PubMedCrossRef
5.
Kimm H, Lee PH, Shin YJ, Park KS, Jo J, Lee Y, Kang HC, Jee SH. Mid-life and late-life vascular risk factors and dementia in Korean men and women. Arch Gerontol Geriatr. 2011;52(3):e117–22.PubMedCrossRef
6.
De Felice FG, Ferreira ST. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes. 2014;63(7):2262–72.CrossRefPubMed
7.
Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004;24(5):816–23.PubMedCrossRef
8.
Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46(1):3–19.CrossRefPubMed
9.
Umegaki H, Makino T, Uemura K, Shimada H, Hayashi T, Cheng XW, Kuzuya M. The associations among insulin resistance, hyperglycemia, physical performance, diabetes mellitus, and cognitive function in relatively healthy older adults with subtle cognitive dysfunction. Front Aging Neurosci. 2017;9:72.PubMedPubMedCentralCrossRef
10.
Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2011;68(1):51–7.PubMedCrossRef
11.
Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316–38.PubMedPubMedCentralCrossRef
12.
Berglund ED, Vianna CR, Donato J Jr, Kim MH, Chuang JC, Lee CE, Lauzon DA, Lin P, Brule LJ, Scott MM, et al. Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice. J Clin Invest. 2012;122(3):1000–9.PubMedPubMedCentralCrossRef
13.
Davis C, Mudd J, Hawkins M: Neuroprotective effects of leptin in the context of obesity and metabolic disorders. Neurobiology of disease 2014, 72 Pt A:61–71.
14.
Gao C, Liu Y, Li L, Holscher C. New animal models of Alzheimer's disease that display insulin desensitization in the brain. Rev Neurosci. 2013;24(6):607–15.PubMedCrossRef
15.
Rosen BS, Cook KS, Yaglom J, Groves DL, Volanakis JE, Damm D, White T, Spiegelman BM. Adipsin and complement factor D activity: an immune-related defect in obesity. Science (New York, NY). 1989;244(4911):1483–7.CrossRef
16.
Schmid A, Hochberg A, Berghoff M, Schlegel J, Karrasch T, Kaps M, Schaffler A. Quantification and regulation of adipsin in human cerebrospinal fluid (CSF). Clin Endocrinol. 2016;84(2):194–202.CrossRef
17.
Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, Kelly ME, Chatterjee Bhowmick D, Murano I, Cohen P, et al. Adipsin is an adipokine that improves beta cell function in diabetes. Cell. 2014;158(1):41–53.PubMedPubMedCentralCrossRef
18.
Wang JS, Lee WJ, Lee IT, Lin SY, Lee WL, Liang KW, Sheu WH. Association between serum Adipsin levels and insulin resistance in subjects with various degrees of glucose intolerance. J Endocr Soc. 2019;3(2):403–10.PubMedCrossRef
19.
Song NJ, Kim S, Jang BH, Chang SH, Yun UJ, Park KM, Waki H, Li DY, Tontonoz P, Park KW. Small molecule-induced complement factor D (Adipsin) promotes lipid accumulation and adipocyte differentiation. PLoS One. 2016;11(9):e0162228.PubMedPubMedCentralCrossRef
20.
Stahl GL, Xu Y, Hao L, Miller M, Buras JA, Fung M, Zhao H. Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol. 2003;162(2):449–55.PubMedPubMedCentralCrossRef
21.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53.CrossRefPubMed
22.
Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili F, Scheltens P, Vellas B, Touchon J. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI working Group of the European Consortium on Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2006;77(6):714–8.PubMedPubMedCentralCrossRef
23.
Liu LS. Chinese guidelines for the management of hypertension. Zhonghua xin xue guan bing za zhi 2011. 2010;39(7):579–615.
24.
Kim JD, Kang SJ, Lee MK, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Lee WY. C-Peptide-Based Index Is More Related to Incident Type 2 Diabetes in Non-Diabetic Subjects than Insulin-Based Index. Endocrinology and metabolism (Seoul, Korea). 2016;31(2):320–7.CrossRef
25.
Herbert V, Brookes RL, Markus HS, Morris RG. Verbal fluency in cerebral small vessel disease and Alzheimer's disease. J Int Neuropsychol Soc. 2014;20(4):413–21.PubMedCrossRef
26.
Xiang Q, Zhang J, Li CY, Wang Y, Zeng MJ, Cai ZX, Tian RB, Jia W, Li XH. Insulin resistance-induced hyperglycemia decreased the activation of Akt/CREB in hippocampus neurons: molecular evidence for mechanism of diabetes-induced cognitive dysfunction. Neuropeptides. 2015;54:9–15.PubMedCrossRef
27.
Yaffe K, Blackwell T, Whitmer RA, Krueger K, Barrett Connor E. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging. 2006;10(4):293–5.PubMed
28.
SR-F J, Sa-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves ML, Moriguti JC, Roriz-Cruz M. (pre) diabetes, brain aging, and cognition. Biochim Biophys Acta. 2009;1792(5):432–43.CrossRef
29.
Sanz CM, Ruidavets JB, Bongard V, Marquie JC, Hanaire H, Ferrieres J, Andrieu S. Relationship between markers of insulin resistance, markers of adiposity, HbA1c, and cognitive functions in a middle-aged population-based sample: the MONA LISA study. Diabetes Care. 2013;36(6):1512–21.PubMedPubMedCentralCrossRef
30.
Tangvarasittichai S, Pongthaisong S, Meemark S, Tangvarasittichai O. Abdominal obesity associated with elevated serum Butyrylcholinesterase activity, insulin resistance and reduced high density lipoprotein-cholesterol levels. Indian J Clinical Biochem. 2015;30(3):275–80.CrossRef
31.
Sallam HS, Tumurbaatar B, Zhang WR, Tuvdendorj D, Chandalia M, Tempia F, Laezza F, Taglialatela G, Abate N. Peripheral adipose tissue insulin resistance alters lipid composition and function of hippocampal synapses. J Neurochem. 2015;133(1):125–33.PubMedPubMedCentralCrossRef
32.
Flier JS, Cook KS, Usher P, Spiegelman BM. Severely impaired adipsin expression in genetic and acquired obesity. Science (New York, NY). 1987;237(4813):405–8.CrossRef
33.
Napolitano A, Lowell BB, Damm D, Leibel RL, Ravussin E, Jimerson DC, Lesem MD, Van Dyke DC, Daly PA, Chatis P, et al. Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass. Int J Obes Relat Metab Disord. 1994;18(4):213–8.PubMed
34.
Maslowska M, Vu H, Phelis S, Sniderman AD, Rhode BM, Blank D, Cianflone K. Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur J Clin Investig. 1999;29(8):679–86.CrossRef
35.
Abu-Farha M, Behbehani K, Elkum N. Comprehensive analysis of circulating adipokines and hsCRP association with cardiovascular disease risk factors and metabolic syndrome in Arabs. Cardiovasc Diabetol. 2014;13:76.PubMedPubMedCentralCrossRef
36.
Schrover IM, van der Graaf Y, Spiering W, Visseren FL. The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease. Eur J Prev Cardiol. 2018;25(14):1548–57.PubMedPubMedCentralCrossRef
37.
Cianflone K. The acylation stimulating protein pathway: clinical implications. Clin Biochem. 1997;30(4):301–12.PubMedCrossRef
38.
Kim TE, Lee DH, Kim YJ, Mok JO, Kim CH, Park JH, Lee TK, Yoo K, Jeong Y, Lee Y, et al. The relationship between cognitive performance and insulin resistance in non-diabetic patients with mild cognitive impairment. Int J Geriatr Psychiatry. 2015;30(6):551–7.PubMedCrossRef
39.
Ekblad LL, Rinne JO, Puukka P, Laine H, Ahtiluoto S, Sulkava R, Viitanen M, Jula A. Insulin resistance predicts cognitive decline: an 11-year follow-up of a nationally representative adult population sample. Diabetes Care. 2017;40(6):751–8.PubMedCrossRef
40.
Gursoy Calan O, Calan M, Yesil Senses P, Unal Kocabas G, Ozden E, Sari KR, Kocar M, Imamoglu C, Senses YM, Bozkaya G, et al. Increased adipsin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome. Clin Endocrinol. 2016;85(6):910–7.CrossRef
41.
Derosa G, Fogari E, D'Angelo A, Bianchi L, Bonaventura A, Romano D, Maffioli P. Adipocytokine levels in obese and non-obese subjects: an observational study. Inflammation. 2013;36(4):914–20.PubMedCrossRef
42.
Zhong Y, Miao Y, Jia WP, Yan H, Wang BY, Jin J. Hyperinsulinemia, insulin resistance and cognitive decline in older cohort. Biomed Environ Sci. 2012;25(1):8–14.PubMed
43.
Sripetchwandee J, Chattipakorn N, Chattipakorn SC. Links between obesity-induced brain insulin resistance, brain mitochondrial dysfunction, and dementia. Front Endocrinol. 2018;9:496.CrossRef
44.
Zhou Y, Fang R, Liu LH, Chen SD, Tang HD. Clinical characteristics for the relationship between Type-2 diabetes mellitus and cognitive impairment: a Cross-sectional study. Aging Dis. 2015;6(4):236–44.PubMedPubMedCentralCrossRef
Metadata
Title
Association between plasma adipsin level and mild cognitive impairment in Chinese patients with type 2 diabetes: a cross-sectional study
Authors
Dan Guo
Yang Yuan
Rong Huang
Sai Tian
Jiaqi Wang
Hongyan Lin
Ke An
Jin Han
Shaohua Wang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2019
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-019-0431-y

Other articles of this Issue 1/2019

BMC Endocrine Disorders 1/2019 Go to the issue

Correspondence

SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class

Research article

Comparison of Five TSH-Receptor Antibody Assays in Graves’ disease: results from an observational pilot study

Research article

Clinical significance of the preoperative main pancreatic duct dilation and neutrophil-to-lymphocyte ratio in pancreatic neuroendocrine tumors (PNETs) of the head after curative resection

Research article

Vitamin D receptor and binding protein polymorphisms in women with polycystic ovary syndrome: a case control study

Research article

Whole-body vibration improves the functional parameters of individuals with metabolic syndrome: an exploratory study

Research article

Total adiponectin in overweight and obese subjects and its response to visceral fat loss

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits